A Phase IIa, Open-label, Multiple Ascending Dose Confirmation Study of the Safety and Tolerability of Intravenous Administration of Brincidofovir in Subjects With Adenovirus Infection or Cytomegalovirus Infection
Latest Information Update: 19 May 2025
At a glance
- Drugs Brincidofovir (Primary)
- Indications Adenovirus infections; Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms ATHENA
- Sponsors SymBio Pharmaceuticals
Most Recent Events
- 20 Jun 2024 Planned number of patients changed from 24 to 52.
- 29 Apr 2024 Planned End Date changed from 31 Dec 2023 to 30 Sep 2026.
- 29 Apr 2024 Planned primary completion date changed from 31 Dec 2023 to 30 Sep 2026.